Figure 2. KRAS^G12D inhibition alters the tumor immune microenvironment.

(A-D) Flow cytometry of indicated cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60h of vehicle (n=6) or MRTX1133 (n=6). Ratio of M1-like (MHC-II⁺) to M2-like (CD206⁺) macrophages in 6419c5 (subcutaneous) tumors after 5 doses of vehicle or MRTX1133 (D, middle). M1/M2 ratio plotted as frequency of total macrophages (D, right). p-values were determined by Student’s unpaired t-test. Error bars indicate SD.

(E) Representative co-immunofluorescent images of F4/80, GFP, and DAPI in vehicle and MRTX1133 treated tumors (6419c5, subcutaneous, 60h). Scale bars, 100 μm. Objective, 20x.

(F) Quantitation of macrophages (F4/80⁺) as percent area per high power field (HPF) in vehicle (n= 3) and MRTX1133 treated tumors (n=3). At least 3 fields of view were averaged per tumor. p-values were determined by Student’s unpaired t-test. Error bars indicate SD.

(G) Flow cytometry of T cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60h of vehicle (n=5) or MRTX1133 (n=5). p-values were determined by Student’s unpaired t-test. Error bars indicate SD. Results are representative of n=3 independent experiments.

(H) Flow cytometry of T cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60h of vehicle (n=15) or MRTX1133 (n=16). Mean fluorescence intensity (MFI) of Ki-67, and GZMB on CD8⁺ T cells. p-values were determined by Student’s unpaired t-test. Error bars indicate SD.

(I) Flow cytometry of T cell subsets from 6419c5 (subcutaneous) tumor draining lymph nodes after 5 doses over 60h of vehicle (n=16) or MRTX1133 (n=16). p-values were determined by Student’s unpaired t-test. Error bars indicate SD.